SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Levamisole / Oxyclozanide Formulation

SECTION 1. IDENTIFICATION

Product name : Levamisole / Oxyclozanide Formulation

Manufacturer or supplier's details
Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
          Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Reproductive toxicity : Category 2
Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)
Specific target organ toxicity - repeated exposure : Category 2 (Brain, Liver)
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Testis)

GHS label elements
Hazard pictograms :

Signal Word : Warning
Hazard Statements : H361d Suspected of damaging the unborn child.  
H371 May cause damage to organs (Central nervous system) if swallowed.  
H373 May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.  
H373 May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

Precautionary Statements : Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Levamisole / Oxyclozanide Formulation

and understood.
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P308 + P311 IF exposed or concerned: Call a doctor.
P308 + P313 IF exposed or concerned: Get medical attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Components</td>
<td></td>
</tr>
<tr>
<td>Chemical name</td>
<td>CAS-No.</td>
</tr>
<tr>
<td>Kaolin</td>
<td>1332-58-7</td>
</tr>
<tr>
<td>Oxyclozanide</td>
<td>2277-92-1</td>
</tr>
<tr>
<td>Levamisole hydrochloride</td>
<td>16595-80-5</td>
</tr>
<tr>
<td>Citric acid</td>
<td>77-92-9</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.
SAFETY DATA SHEET  
according to the OSHA Hazard Communication Standard

Levamisole / Oxyclozanide Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.9</td>
<td>09/30/2023</td>
<td>5360104-00010</td>
<td>04/04/2023</td>
<td>12/19/2019</td>
</tr>
</tbody>
</table>

Most important symptoms and effects, both acute and delayed:
- Suspected of damaging the unborn child.
- May cause damage to organs if swallowed.
- May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders:
- First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician:
- Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

<table>
<thead>
<tr>
<th>Suitable extinguishing media</th>
<th>Water spray</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol-resistant foam</td>
<td></td>
</tr>
<tr>
<td>Carbon dioxide (CO2)</td>
<td></td>
</tr>
<tr>
<td>Dry chemical</td>
<td></td>
</tr>
</tbody>
</table>

Unsuitable extinguishing media:
- None known.

Specific hazards during fire fighting:
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Silicon oxides
- Metal oxides
- Chlorine compounds
- Nitrogen oxides (NOx)

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for fire-fighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g., by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable...
absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe mist or vapors.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaolin</td>
<td>1332-58-7</td>
<td>TWA (Respirable particulate matter)</td>
<td>2 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable)</td>
<td>5 mg/m³</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (total)</td>
<td>10 mg/m³</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (total dust)</td>
<td>15 mg/m³</td>
<td>OSHA Z-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable fraction)</td>
<td>5 mg/m³</td>
<td>OSHA Z-1</td>
</tr>
<tr>
<td>Oxyclonide</td>
<td>2277-92-1</td>
<td>TWA</td>
<td>0.4 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Levamisole hydrochloride</td>
<td>16595-80-5</td>
<td>TWA</td>
<td>20 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>
Further information:

<table>
<thead>
<tr>
<th>Skin</th>
<th>Wipe limit</th>
<th>Internal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>200 µg/100 cm²</td>
<td></td>
</tr>
</tbody>
</table>

**Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

**Personal protective equipment**

**Respiratory protection**

General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn.

Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**

**Material**: Chemical-resistant gloves

**Remarks**: Consider double gloving.

**Eye protection**

Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**

Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hygiene measures**

If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Levamisole / Oxyclozanide Formulation

<table>
<thead>
<tr>
<th>Appearance</th>
<th>liquid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Color</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>No data available</td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
</tbody>
</table>
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:
Kaolin:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Remarks: Based on data from similar materials
Acute inhalation toxicity: LC50 (Rat): > 2.07 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity
Remarks: Based on data from similar materials
Acute dermal toxicity: LD50 (Rat): > 5,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials
Levamisole / Oxyclozanide Formulation

**Oxyclozanide:**
- **Acute oral toxicity**: LD50 (Rat): 3,519 mg/kg
  Target Organs: Central nervous system
- **Acute toxicity (other routes of administration)**: LDLo (sheep): 10 mg/kg
  Application Route: Intravenous

**Levamisole hydrochloride:**
- **Acute oral toxicity**:
  - LD50 (Rat): 180 mg/kg
  - LD50 (Mouse): 223 mg/kg
  - LD50 (Rabbit): 458 mg/kg
- **Acute inhalation toxicity**: Remarks: No data available
- **Acute dermal toxicity**: Remarks: No data available

**Citric acid:**
- **Acute oral toxicity**: LD50 (Mouse): 5,400 mg/kg
- **Acute dermal toxicity**: LD50 (Rat): > 2,000 mg/kg
  Method: OECD Test Guideline 402
  Assessment: The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Kaolin:**
- **Species**: Rabbit
- **Method**: OECD Test Guideline 404
- **Result**: No skin irritation
- **Remarks**: Based on data from similar materials

**Oxyclozanide:**
- **Remarks**: Not classified due to lack of data.

**Levamisole hydrochloride:**
- **Remarks**: No data available

**Citric acid:**
- **Species**: Rabbit
- **Method**: OECD Test Guideline 404
- **Result**: No skin irritation
Serious eye damage/eye irritation
Not classified based on available information.

Components:

Kaolin:
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

Oxyclozanide:
Remarks: Not classified due to lack of data.

Levamisole hydrochloride:
Remarks: No data available

Citric acid:
Species: Rabbit
Result: Irritation to eyes, reversing within 21 days
Method: OECD Test Guideline 405

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Oxyclozanide:
Routes of exposure: Dermal
Remarks: Not classified due to lack of data.

Levamisole hydrochloride:
Remarks: No data available

Germ cell mutagenicity
Not classified based on available information.

Components:

Oxyclozanide:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: positive
Levamisole / Oxyclozanide Formulation

Test Type: Mouse Lymphoma
Result: positive

Genotoxicity in vivo:
Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

**Levamisole hydrochloride:**
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

**Citric acid:**
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: in vitro micronucleus test
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo:
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

**Carcinogenicity**
Not classified based on available information.

**Components:**

**Oxyclozanide:**
Remarks: Not classified due to lack of data.

**Levamisole hydrochloride:**
Species: Mouse
Application Route: Oral
Levamisole / Oxyclozanide Formulation

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

Oxyclozanide:

Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat, male and female
Application Route: Oral
General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.
Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.
Result: No effects on fertility.

Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects., No effects on fertility.
Effects on fetal development: Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 200 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

Test Type: Development
Species: Rat
Application Route: Oral
General Toxicity Maternal: LOAEL: 100 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 32 mg/kg body weight
Result: Fetotoxicity., Skeletal malformations.

Reproductive toxicity - Assessment: Suspected of damaging the unborn child.

Levamisole hydrochloride:
 Effects on fertility: Test Type: Three-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Result: No significant adverse effects were reported

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 20 mg/kg body weight
Result: Fetotoxicity.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 40 mg/kg body weight
Result: Fetotoxicity.

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

Citric acid:
 Effects on fetal development: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

STOT-single exposure
May cause damage to organs (Central nervous system) if swallowed.
Components:

Oxyclozanide:
- Routes of exposure: Oral
- Target Organs: Central nervous system
- Assessment: May cause damage to organs.

Citric acid:
- Assessment: May cause respiratory irritation.

STOT-repeated exposure
May cause damage to organs (Brain, Liver) through prolonged or repeated exposure. May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

Components:

Oxyclozanide:
- Target Organs: Brain, Liver
- Assessment: May cause damage to organs through prolonged or repeated exposure.

Levamisole hydrochloride:
- Target Organs: Blood, Testis
- Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Oxyclozanide:
- Species: Rat
- NOAEL: 9 mg/kg
- LOAEL: 44.5 mg/kg
- Application Route: Oral
- Exposure time: 3 Months
- Target Organs: Brain, Liver, spleen, Adrenal gland
- Symptoms: Liver effects

Species: Dog
- NOAEL: 5 mg/kg
- LOAEL: 25 mg/kg
- Application Route: Oral
- Exposure time: 3 Months
- Target Organs: Brain, Liver
- Symptoms: blood effects, alteration in liver enzymes

Levamisole hydrochloride:
- Species: Rat
- NOAEL: 2.5 mg/kg
Levamisole / Oxyclozanide Formulation

Application Route: Oral
Exposure time: 18 Months
Target Organs: Testis

Species: Dog
LOAEL: 20 mg/kg
Application Route: Oral
Exposure time: 18 Months
Target Organs: Blood

Species: Dog
LOAEL: 40 mg/kg
Application Route: Oral
Exposure time: 3 Months

Citric acid:
Species: Rat
NOAEL: 4,000 mg/kg
LOAEL: 8,000 mg/kg
Application Route: Ingestion
Exposure time: 10 Days

Aspiration toxicity
Not classified based on available information.

Components:
Oxyclozanide:
Ingestion: Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

Experience with human exposure

Components:
Oxyclozanide:
Ingestion: Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

Levamisole hydrochloride:
Ingestion: Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:
Kaolin:
Toxicity to fish (Chronic toxicity): NOELR (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 30 d
Oxyclozanide:
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.69 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Levamisole hydrochloride:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): 64 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Citric acid:
Toxicity to fish:
LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): 1,535 mg/l
Exposure time: 24 h

Persistence and degradability

Components:

Oxyclozanide:
Stability in water: Hydrolysis: 50 % (156 d)
Method: OECD Test Guideline 111

Citric acid:
Biodegradability:
Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Bioaccumulative potential

Components:

Oxyclozanide:
Partition coefficient: n-octanol/water:
log Pow: 3.99
pH: 7
Method: OECD Test Guideline 107

Citric acid:
Partition coefficient: n-octanol/water:
log Pow: -1.72
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Levamisole / Oxyclozanide Formulation

Mobility in soil

Components:

Oxyclozanide:
Distribution among environmental compartments: log Koc: 4.83
Method: OECD Test Guideline 106

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide)
Class: 9
Packing group: III
Labels: 9
Environmentally hazardous: yes

IATA-DGR
UN/ID No.: UN 3082
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (Oxyclozanide)
Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 964
Packing instruction (passenger aircraft): 964
Environmentally hazardous: yes

IMDG-Code
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Oxyclozanide)
Class: 9
Packing group: III
### SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

**Levamisole / Oxyclozanide Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.9</td>
<td>09/30/2023</td>
<td>5360104-00010</td>
<td>04/04/2023</td>
<td>12/19/2019</td>
</tr>
</tbody>
</table>

- **Labels**: 9
- **EmS Code**: F-A, S-F
- **Marine pollutant**: yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
Not applicable for product as supplied.

**Domestic regulation**

**49 CFR**
- **UN/ID/NA number**: UN 3082
- **Proper shipping name**: Environmentally hazardous substance, liquid, n.o.s. (Oxyclozanide)
- **Class**: 9
- **Packing group**: III
- **ERG Code**: 171
- **Marine pollutant**: yes (Oxyclozanide)
- **Remarks**: Above applies only to containers over 119 gallons or 450 liters. Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

**Special precautions for user**
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### SECTION 15. REGULATORY INFORMATION

**CERCLA Reportable Quantity**
This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**
This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**
This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards**
- Reproductive toxicity
- Specific target organ toxicity (single or repeated exposure)

**SARA 313**
- This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**US State Regulations**

**Pennsylvania Right To Know**
- **Water**: 7732-18-5
- **Kaolin**: 1332-58-7
- **Oxyclozanide**: 2277-92-1
Levamisole / Oxydolanide Formulation

California Permissible Exposure Limits for Chemical Contaminants
Kaolin 1332-58-7

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:

HMIS® IV:

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/'" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL : USA. NIOSH Recommended Exposure Limits
OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA : 8-hour, time-weighted average
NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with...
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Levamisole / Oxyclozanide Formulation

Version | Revision Date | SDS Number | Date of last issue | Date of first issue
1.9     | 09/30/2023    | 5360104-00010 | 04/04/2023         | 12/19/2019

x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8